Alterity Therapeutics Ltd. ( (AU:ATH) ) has issued an update.
Alterity Therapeutics Ltd. announced the issuance of 2,470,521,806 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act, as permitted by section 708A(5)(e). The company has confirmed compliance with relevant provisions of the Corporations Act and stated that there is no excluded information to disclose, ensuring transparency and adherence to regulatory requirements.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd. operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases. The company is listed on both the Australian Securities Exchange (ASX: ATH) and NASDAQ (ATHE), indicating its active participation in global financial markets.
Average Trading Volume: 100
Technical Sentiment Signal: Strong Buy
Current Market Cap: $32.18M
See more insights into ATH stock on TipRanks’ Stock Analysis page.